TwinBeech Capital’s 10x Genomics TXG Stock Holding History

TwinBeech Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,450	Closed	-$590K	–	853
2025 Q3	$590K	Buy	+50,450	New	+$658K	0.02%	374
2025 Q2	–	Sell	-18,244	Closed	-$159K	–	985
2025 Q1	$159K	Buy	18,244 +5,739	+46%	+$72.3K	﹤0.01%	670
2024 Q4	$180K	Buy	+12,505	New	+$197K	﹤0.01%	565
2024 Q3	–	Sell	-19,015	Closed	-$370K	–	902
2024 Q2	$370K	Buy	+19,015	New	+$498K	0.01%	469
2023 Q3	–	Sell	-5,521	Closed	-$308K	–	903
2023 Q2	$308K	Buy	+5,521	New	+$299K	0.01%	543
2022 Q2	–	Sell	-89,975	Closed	-$6.84M	–	738
2022 Q1	$6.84M	Buy	+89,975	New	+$7.87M	0.3%	100
2021 Q4	–	Sell	-2,606	Closed	-$379K	–	821
2021 Q3	$379K	Buy	+2,606	New	+$447K	0.03%	474
2020 Q4	–	Sell	-3,151	Closed	-$393K	–	617
2020 Q3	$393K	Buy	+3,151	New	+$331K	0.09%	309
2020 Q2	–	Sell	-5,435	Closed	-$339K	–	495
2020 Q1	$339K	Buy	+5,435	New	+$424K	0.14%	208

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TwinBeech Capital's TXG Position: Q4 2025 in Review

TwinBeech Capital sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 50,450 shares — an estimated $590K sold.

TwinBeech Capital first reported a position in TXG in Q1 2020 and held it in 9 quarters. The position peaked at $6.84M in Q1 2022. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

TwinBeech Capital reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
TwinBeech Capital sold 50,450 10x Genomics shares in Q4 2025, an estimated $590K.
TwinBeech Capital first reported a position in 10x Genomics in Q1 2020 and held it in 9 quarters.
TwinBeech Capital's 10x Genomics position peaked at $6.84M in Q1 2022.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on TwinBeech Capital's 13F filing for Q4 2025, filed 17 Feb 2026.